TEZSPIRE
Q2 2026 sales rose 42% to $486 million; a Phase 3 study in eosinophilic esophagitis is due to finish in H2 2026.
The numbers
What it is
Asthma medicine that blocks TSLP, developed with AstraZeneca. It is sold as a respiratory biologic and is one of Amgen's main growth products.
Why it matters to the stock. TEZSPIRE's growth and any new indication, such as eosinophilic esophagitis, extend the product's revenue base beyond asthma.
News
TEZSPIRE meets both co-primary endpoints in Phase 3 eosinophilic esophagitis trial
Amgen and AstraZeneca reported positive topline results from the Phase 3 CROSSING trial of TEZSPIRE in eosinophilic esophagitis on August 27, 2026.
Amgen's 2026 outlook: $38.2B to $39.4B revenue and $22.30 to $23.50 non-GAAP EPS
Alongside its second-quarter results, Amgen set full-year 2026 guidance of $38.2 billion to $39.4 billion in total revenues, non-GAAP diluted EPS of $22.30 to $23.50, and GAAP diluted EPS of $15.80 to $17.08.